Julian Vance

Fasting windows can help glucose control and weight in some adults, but timing is secondary. Safety, adherence and medical supervision decide if it works.

Fasting can improve some markers, but glucose-lowering medicine can alter risk. If you use insulin or SGLT2 drugs, get medical guidance before changing timing.

Time-restricted eating can improve some weight and glucose markers, but medication risks, adherence, and long-term outcomes are still uncertain.

A new trial suggests an 8–10-hour eating window can modestly improve metabolic risk markers, but it is a routine—not a replacement for care.

Liver fat is closely tied to insulin resistance, but it is a metabolic risk signal, not a verdict. The useful next step is fibrosis risk, not panic.

Glycaemic variability can reveal glucose swings that HbA1c hides, but the evidence supports using it as a clinical clue, not a stand-alone diagnosis.

OMAD can reduce eating opportunities, but evidence points to calorie reduction and adherence, not proven longevity gains, as the main explanation for adults.

Fasted training may shift fuel use and insulin responses, but evidence does not make it a fat-loss shortcut or a default choice for everyone.

After a longer fast, the first meal matters less as a ritual than as a metabolic transition. Here is when caution is useful and when it is overkill.

Metabolic flexibility describes how readily your body switches between glucose and fat as fuel. The science is clearer on exercise than on supplements.